文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

瑞戈非尼对比局部标准治疗用于不再适合局部区域治疗的2-3级脑膜瘤患者:一项II期随机对照试验(MIRAGE研究)

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).
PubMed 文献 · Trials · 2025-08-04

MIRAGE是一项多中心、开放标签、随机对照II期试验,计划入组94例术后及放疗后进展的2/3级脑膜瘤患者,1:1随机接受瑞戈非尼(160 mg口服,服3周停1周)或局部标准治疗,主要终点为6个月无进展生存期。

要点

  • 瑞戈非尼为口服多酪氨酸激酶抑制剂,对VEGFR1/2/3高选择性,同时抑制PDGFRβ、FGFR1及c-RAF/RAF1、BRAF相关致癌信号。
  • 入组要求WHO 2021分类组织学确诊2级或3级脑膜瘤,RANO标准影像学进展且至少1个可测量病灶(最小10×10 mm),不适合进一步手术和/或放疗,WHO体能状态0-1。
  • 主要终点为6个月无进展生存期,次要终点包括总生存期、客观缓解率、疾病控制率、安全性和健康相关生活质量。

核心结论

  • MIRAGE是一项II期试验,旨在确定瑞戈非尼在延长不适合进一步手术和/或放疗的2-3级脑膜瘤患者无进展生存期方面的作用。

研究设计与样本

  • 多中心、开放标签、对照、随机II期临床试验(MIRAGE,NCT06275919),计划随机入组94例术后及放疗后进展的2/3级脑膜瘤患者,1:1随机分配。
  • 试验由Istituto Oncologico Veneto(IOV-IRCCS)发起,为学术试验,2024年9月启动,计划在意大利15个神经肿瘤中心招募患者,预计研究时长18个月。

主要发现

  • 试验正在入组中,原文未报告结果。

关键数值与推荐

  • 试验组瑞戈非尼160 mg口服,服3周停1周;对照组为局部标准治疗(如贝伐珠单抗、羟基脲、生长抑素类似物)。
  • 主要终点为6个月无进展生存期;次要终点包括总生存期、客观缓解率、疾病控制率、安全性和健康相关生活质量。
  • 入组标准包括WHO 2021分类组织学确诊2级或3级脑膜瘤、RANO标准影像学进展且基线MRI至少1个可测量病灶(最小10×10 mm)、不适合进一步手术和/或放疗、WHO体能状态0-1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regorafenib is an oral multi-tyrosine kinase (RTK) inhibitor. It exhibits high selectivity for VEGFR1/2/3, while also inhibiting PDGFRβ, FGFR1, and oncogenic signaling cascades involving c-RAF/RAF1 and BRAF. These pathways are highly expressed in meningiomas, particularly in high-grade meningiomas. METHODS: The MIRAGE trial (NCT06275919) is a multicenter, open-label, controlled, randomized phase 2 clinical trial evaluating grade 2/3 meningioma patients who have progressed following surgery and radiotherapy. A total of 94 participants are being randomized (1:1) to receive either regorafenib (160 mg orally for 3 weeks on, 1 week off) or local standard-of-care therapies (e.g., bevacizumab, hydroxyurea, somatostatin analogs). Major inclusion criteria include histological confirmation of grade 2 or grade 3 meningioma according to the WHO 2021 classification, radiologically documented progression according to RANO criteria with at least 1 measurable lesion (minimum 10 × 10 mm) on baseline MRI, ineligibility for further surgery and/or radiotherapy, and a WHO performance status of 0-1. The primary endpoint is 6-month progression-free survival (6m-PFS) and secondary endpoints include overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety, and health-related quality of life. Exploratory analysis will also be performed. MIRAGE, initiated in September 2024, is an academic trial promoted by the Istituto Oncologico Veneto, IOV-IRCCS, and will recruit patients across 15 neuro-oncology centers in Italy with an estimated study duration of 18 months. DISCUSSION: MIRAGE is a phase 2 trial designed to determine the role of regorafenib in prolonging the PFS of grade 2-3 meningioma patients ineligible for further surgery and/or radiotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT06275919. Registered before start of inclusion, 7 February 2024. EuCT no. 2024-510954-28.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bosio A, Cerretti G, Padovan M, et al. Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). Trials. 2025. PMID: 40759981. doi:10.1186/s13063-025-08997-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。